NIH researchers have have described a novel autoinflammatory disorder called "Lyn kinase-associated vasculopathy and liver fibrosis" (LAVLI), based on a mutation in the LYN gene (that encodes the Lyn kinase protein). They discovered that increased Lyn kinase activity promotes systemic inflammation, by altering microvascular permeability and neutrophil recruitment, while at the same time promoting hepatic fibrosis.
The Cleveland Clinic Journal has published a full-read review of postural orthostatic tachycardia syndrome (POTS), a condition often seen in clinic with symptoms like fibromyalgia, but is clinically diagnosed with finding sustained tachycardia upon standing without orthostatic hypotension.
Dr. John Cush RheumNow
2 years 10 months ago
Best of 2023: 25 Great Women in Rheumatology
https://t.co/9WgGbpILGb https://t.co/YN8QAHtyab
Dr. John Cush RheumNow
2 years 10 months ago
NEJM - Clinical Images. Sleeve Sign and Inverse Gottron’s Papules in Anti-MDA5 Dermatomyositis. Erythematous plaques/patches on lateral aspects upper arms &; red patches, papules, pustules on ventral palms https://t.co/UHKGePi6TK
Dr. John Cush RheumNow
2 years 10 months ago
Livedo reticularis is a painless, cyanotic cutaneous mottling in a fishnet pattern, often on extremities > trunk & exaggerated by cold. NOT specific but may be assoc w/ fibromyalgia, Raynauds, atheromatous or autoimmune Dz, hyperviscosity, thrombotic Dz https://t.co/8tGz1hIDiA https://t.co/3mw2RwTEeL
Dr. John Cush RheumNow
2 years 10 months ago
- High mortality risk predictors in patients with anti-MDA5 dermatomyositis include:
- rapidly progressive interstitial lung disease
- anti-Ro52 antibody
- age > 57 years
(based on study of 126 MDA-5+ DM pts)
https://t.co/8bw1zpEOIh https://t.co/LKXMYtr7hU
Dr. John Cush RheumNow
2 years 10 months ago
DA Approves Canakinumab for Gout Flares The US FDA has approved canakinumab \ Ilaris\ for the treatment of gout flares in adults who cannot be treated with NSAIDs, colchicine, or repeated courses of corticosteroids. https://t.co/OX3wIajQtm https://t.co/tMDMc8ZKE8
Dr. John Cush RheumNow
2 years 10 months ago
Great content. Dr Andrea Fava will present this data and other research on lupus biomarkers at https://t.co/2dcFVgu8z6 on Jan 27, 2024. Can't wait! https://t.co/IOJIyDAmeG
Dr. John Cush RheumNow
2 years 10 months ago
2022 ACR Classification Criteria for GCA: \ must be \>50yrs\ 6 points needed for #GCA AM stiff should/neck 2 Visual loss 3 Jaw Claud 2 Temp HA 2 Scalp tender 2 Hi ESR/CRP 3 Bx or US 5 axillary 2 PEG Aorta 2 https://t.co/LfkIZKnLZi https://t.co/LdQOoRfG5V
A new MSK syndrome of inflammatory enthesitis/arthritis/tenosynovitis has been described in atopic dermatitis (AD) patients treated with the IL-4 receptor antagonist, dupilumab.
The COLCHICORT trial in patients with acute calcium pyrophosphate crystal arthritis (CPPD) demonstrated equivalent efficacy for both colchicine and prednisone, yet different safety signals were seen.
Dr. John Cush RheumNow
2 years 10 months ago
RHEUMATOLOGIST SURVEY QUESTION: Is TYK2 part of the Janus Kinase family?
Click here to answer >> https://t.co/Uzad4Tp7YV
Dr. John Cush RheumNow
2 years 10 months ago
ICYMI: Effective Treatments for Rheumatoid Arthritis ILD
The ACR guidelines for the diagnosis and management of interstitial lung disease, which includes RA-ILD, has been one of the most controversial topics in the runup to ACR Convergence.
https://t.co/tvXEeaTbRq https://t.co/Dq3NcSAGhf

